National Spotlight Features Phio’s Innovative RNAi Technology Platform
April 03, 2024 07:30 ET
|
Phio Pharmaceuticals Corp.
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp....
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
April 02, 2024 09:05 ET
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals, next-generation RNA therapeutics developer, appoints Dr. Chris Storgard as Chief Medical Officer
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
April 02, 2024 07:30 ET
|
Phio Pharmaceuticals Corp.
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments,...
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
March 21, 2024 07:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
March 13, 2024 14:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
March 06, 2024 10:30 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Global RNAi Technology Market Projected to Reach $1.9 Billion by 2028: Precision Medicine Integration Accelerating Personalized Treatments
February 12, 2024 04:24 ET
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technology Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's...
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
January 31, 2024 08:00 ET
|
Phio Pharmaceuticals Corp.
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
RNA-based Therapeutics Market Outlook Report, 2023-2034: Personalized Medicine Adoption, Investment Inflows, and Pharma Collaborations Fueling Global Industry Growth
January 24, 2024 14:22 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global RNA-based Therapeutics Market" report has been added to ResearchAndMarkets.com's offering. The Global RNA-based Therapeutics Market was...
RNAi Therapeutics Market Global Industry Analysis and Forecasts to 2030: A $20.23 Billion Market in 2030, with a CAGR of a 7.69% During 2023-2030
January 17, 2024 12:03 ET
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ResearchAndMarkets.com's...